# 5 Scenarios for the Future of CRISPR Gene Editing

Over the next 15 years, CRISPR gene editing will shift from multi-million-dollar, *ex vivo* therapies for rare diseases to highly accessible, *in vivo* treatments utilizing reversible epigenetic silencing. However, this clinical evolution will be heavily dictated by healthcare reimbursement models, fragmented global regulations, DIY biosecurity risks, and an ongoing moratorium on heritable designer babies.

## The State of CRISPR in 2026

When scientists first repurposed a bacterial immune system into a programmable gene-editing tool in 2012, it was universally hailed as the holy grail of genetic engineering [cite: 1, 2]. By utilizing a guide RNA (gRNA) to locate a specific sequence of DNA and a Cas9 enzyme to cut it, researchers gained the unprecedented ability to essentially rewrite the code of life [cite: 2, 3, 4]. 

Transitioning from a basic laboratory concept to a fully FDA-approved medical treatment in just 11 years represents one of the most remarkable achievements in the history of modern medicine [cite: 5]. That historic milestone was officially reached in December 2023 with the approval of Casgevy (exagamglogene autotemcel), the world's first CRISPR-based therapy, designed to functionally cure severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) [cite: 5, 6, 7]. 

As of mid-2026, the clinical data for these early therapies is overwhelmingly positive and remarkably durable. Long-term follow-ups from the pivotal CLIMB-121 and CLIMB-131 trials, spanning more than five and a half years for SCD patients and over six years for TDT patients, show that the underlying gene-editing effect remains stable [cite: 7, 8]. According to data presented at the 2025 European Hematology Association (EHA) Congress, 95.6% of treated SCD patients remained completely free from severe vaso-occlusive crises for at least 12 consecutive months, while 98.2% of TDT patients achieved transfusion independence [cite: 7, 8]. 

Yet, despite this profound scientific triumph, only about 340 patients globally had actually received Casgevy by the first quarter of 2026 [cite: 6]. The principal barrier is no longer the science, but the economics: the therapy costs $2.2 million per patient, requires grueling myeloablative chemotherapy conditioning with busulfan, and demands complex, centralized autologous cell manufacturing [cite: 6, 7, 9].

As we look toward 2041, the gene-editing landscape is rapidly maturing beyond these initial bottlenecks. Biotechnology startups are building reusable therapeutic platforms, major pharmaceutical companies are investing billions into single-dose cures, and regulatory agencies worldwide are adapting their frameworks to accommodate the era of personalized genetic medicine [cite: 10, 11]. To understand whether CRISPR will live up to its transformative potential over the next decade and a half, we must examine five distinct scenarios shaping its trajectory in clinical practice, healthcare economics, and global policy.

## Scenario 1: The Affordability Crisis and New Insurance Models

The most immediate and consequential hurdle facing the gene therapy revolution is pure economics. Developing a novel gene therapy costs an estimated $5 billion—more than five times the average cost of developing traditional small-molecule drugs [cite: 12]. Consequently, the first generation of genomic therapies has entered the market with staggering price tags. While Casgevy is priced at $2.2 million, other gene therapies like Zolgensma cost $2.1 million, and Hemgenix holds a list price of $3.5 million per one-time treatment [cite: 9, 13, 14, 15].

### The Deepening Threat to Health Equity

If these prices remain static, CRISPR threatens to drastically deepen existing health inequalities. From a fundamental public health perspective, medical breakthroughs historically benefit society's most advantaged populations first, leaving marginalized and minority groups behind [cite: 13]. This dynamic is acutely relevant for sickle cell disease, a condition that disproportionately affects people of African descent and has long been neglected by the traditional medical establishment [cite: 5, 9]. 

While Casgevy's $2.2 million price tag was widely anticipated by market analysts, it places immense strain on both private and public healthcare systems. Economic models suggest that if a sickle cell genomic therapy were priced at $1 million per patient and made available to all eligible individuals, it would cost US Medicaid programs $55 billion—roughly 85% of Medicaid's total spending on outpatient drugs in a given year [cite: 14, 16]. When accounting for the actual $2.2 million list price, the budget impact becomes mathematically paralyzing for many state-funded systems.

Insurance companies are struggling to absorb these "shock claims" [cite: 15]. The US healthcare system is traditionally built around managing chronic illnesses with payments spread out over decades, making it structurally ill-equipped for one-time, multi-million-dollar curative interventions [cite: 17, 18]. Because patients frequently switch insurance providers due to employment changes (enrollee churn), a health plan that pays $2.2 million today may not reap the financial rewards of the patient's long-term health if that patient switches to a different employer's plan a few years later [cite: 19].



### The Shift Toward Outcomes-Based Agreements

To prevent the insurance system from buckling under the weight of genetic cures, the pharmaceutical and payer industries are aggressively moving toward innovative payment models.

[image delta #1, 0 bytes]

 By 2040, the standard mechanism for purchasing a gene therapy will likely not be a lump-sum transaction, but an outcomes-based agreement (OBA) or an amortized annuity [cite: 15, 20]. 

Under an outcomes-based model, the cost of the drug is tied directly to its real-world clinical performance over time. If a patient receives a multi-million-dollar sickle cell cure but experiences a severe pain crisis three years later, the pharmaceutical manufacturer is contractually obligated to issue a rebate, refund, or price adjustment to the insurer [cite: 17, 21]. Similarly, a "warranty" model requires manufacturers to purchase a patient-specific policy that reimburses treatment costs if the outcome is suboptimal [cite: 15].

Annuity models take this a step further by spreading the payment over time. Instead of paying $2.2 million upfront, a government or private payer might pay a fixed installment per year for five years—provided the patient remains cured [cite: 20, 21]. One health economics analysis evaluating budget impact in England demonstrated that paying an annuity over three years yielded a budget impact that allowed for a 23% increase in the total number of patients treated under a fixed budget, compared to upfront lump-sum payments [cite: 20]. To facilitate this in the US, the Centers for Medicare & Medicaid Services (CMS) launched an access model in 2025 specifically to support these types of agreements for sickle cell treatments, offering technical support and funding to participating states [cite: 6, 15, 20].

However, the long-term viability of these financial models depends on massive improvements in healthcare data infrastructure. Tracking a single patient's outcomes across decades—even as they switch jobs and insurance providers—requires robust, standardized longitudinal data registries that do not currently exist at scale in the highly fragmented US system [cite: 18, 19, 22]. Europe is slightly ahead in this regard; for example, Spain's Valtermed registry system is specifically designed to collect real-world clinical data to inform cost-effectiveness analyses and enforce outcomes-based rebates for advanced therapies [cite: 22].

## Scenario 2: Moving Inside the Body and Beyond the Cut

The second major scenario defining the next 15 years involves how CRISPR is physically delivered to patients and how it interacts with the human genome. Today, the most successful and clinically proven applications are *ex vivo* (out of the body) procedures [cite: 23, 24]. 

In an *ex vivo* autologous cell therapy, stem cells are extracted from a patient, shipped to a highly specialized centralized manufacturing facility, edited using CRISPR to correct the targeted mutation, and then infused back into the patient [cite: 24, 25, 26]. While highly controlled, this process is grueling. It takes months to complete, costs tens of thousands of dollars just in logistics, requires the patient to undergo highly toxic myeloablative chemotherapy to destroy their existing bone marrow, and relies heavily on a limited number of specialized medical centers [cite: 7, 14, 24].

### The Push for In Vivo Delivery Constraints

To effectively scale CRISPR to millions of people—particularly for common conditions like cardiovascular disease—treatments must become *in vivo*. In an *in vivo* model, the editing machinery is administered directly into the patient's body via an intravenous infusion or an injection, much like a standard pharmaceutical biologic [cite: 23, 24]. 

The primary technical bottleneck for *in vivo* editing has historically been packaging. The classic Cas9 protein, originally derived from *Streptococcus pyogenes*, is physically quite large. It is often too large to fit efficiently inside adeno-associated viruses (AAVs), which are the standard, highly proven delivery vehicles used to ferry genetic instructions safely into human cells [cite: 27, 28]. AAVs possess a strict, inflexible payload limit of approximately 4.7 kilobases, forcing researchers to constantly search for smaller, more compact alternatives [cite: 29].

By early 2026, researchers began engineering highly compact CRISPR systems designed explicitly for these viral constraints. For instance, researchers at the University of Texas at Austin, in partnership with Metagenomi Therapeutics, identified a naturally occurring bacterial nuclease enzyme called Al3Cas12f. Through machine learning and structural analysis, they optimized it into an engineered variant known as RKK, which is tiny enough to fit perfectly inside AAV delivery systems while dramatically improving gene-editing efficiency from less than 10% to more than 80% in human cells [cite: 27, 28]. 

Concurrently, non-viral delivery methods, such as the lipid nanoparticles (LNPs) utilized in the mRNA COVID-19 vaccines, are showing massive clinical promise [cite: 10, 30]. Clinical trials are currently ongoing using LNPs to deliver CRISPR directly to the liver to permanently silence genes responsible for severe cardiovascular diseases. For example, CRISPR Therapeutics has advanced its CTX310 program into Phase 1b clinical trials, utilizing LNPs to target the ANGPTL3 gene to treat severe hypertriglyceridemia, while Eli Lilly committed up to $1.3 billion in a partnership with Verve Therapeutics to target the PCSK9 gene for heart disease [cite: 10, 11, 31].

### Base Editing, Prime Editing, and Epigenetics: Gentler Genetic Brakes

Perhaps the most profound technological shift over the next 15 years will be the transition from explicitly cutting DNA to simply turning it off or swapping individual letters without severing the double helix. 

Early and current iterations of CRISPR work by inducing double-stranded breaks (DSBs) in the DNA [cite: 32, 33]. While highly effective at disrupting faulty genes, breaking both strands of the DNA helix carries the inherent risk of unintended off-target mutations, cellular toxicity, and large structural chromosomal rearrangements [cite: 33, 34]. A 2026 study published in *Science* even suggested that repaired DNA breaks could cause "chromatin fatigue," leaving lasting, heritable disruptions to how the genome is structurally organized and functions, extending risks beyond simple sequence errors [cite: 35].

To mitigate these risks, the field is rapidly adopting **Base Editing** and **Prime Editing**. Base editors chemically convert one DNA letter into another (e.g., changing a C to a T) without breaking the double helix, while Prime editors act as a "search-and-replace" function, writing new genetic information directly into a specific DNA site [cite: 10, 36]. In late 2025, Prime Medicine published the first-ever clinical data showing the successful and safe use of prime editing in humans to treat Chronic Granulomatous Disease (CGD) [cite: 10].

However, the ultimate future of reversible gene therapy lies in **Epigenetic Editing**. Rather than acting as "molecular scissors" that sever the DNA, epigenetic CRISPR acts as a molecular switch [cite: 33, 37]. By utilizing a catalytically deactivated Cas protein (dCas9) that serves only as a highly precise DNA-sequence locator, scientists can fuse it to an epigenetic effector domain (such as DNA methyltransferases like DNMT3A, or demethylases like TET1) [cite: 37, 38]. These effectors add or remove chemical tags (methyl groups) on the outside of the DNA structure. These tags act as genetic brakes or accelerators, silencing a gene or amplifying its protein production without ever altering the underlying genetic code [cite: 10, 33, 38].

[image delta #2, 0 bytes]





This gentler, non-cutting approach holds immense clinical potential. In early 2025, a team of scientists achieved a historic milestone by utilizing a personalized *in vivo* epigenetic CRISPR therapy to save an infant born with carbamoyl phosphate synthetase I (CPS1) deficiency, developing and administering the drug in just six months [cite: 10]. Epigenetic editing could also offer a significantly safer route for treating sickle cell disease by simply removing the chemical tags that naturally silence fetal hemoglobin after birth, thereby turning a dormant, healthy blood gene back on to compensate for the mutated adult hemoglobin [cite: 33]. Because it does not permanently shatter DNA, epigenetic editing is theoretically reversible, offering a vastly superior safety profile for widespread clinical use in complex conditions ranging from autoimmune disorders to cancer [cite: 10, 37].

## Scenario 3: The Democratization of Biology and Biosecurity Risks

As CRISPR technology becomes cheaper, more precise, and vastly easier to manipulate, it is inevitably bleeding out of highly regulated academic and corporate laboratories and into the hands of the general public. The democratization of biology is actively fostering a global subculture of "biohackers" and do-it-yourself (DIY) amateur scientists experimenting in community labs, garages, and living rooms [cite: 39, 40, 41].

Mail-order CRISPR kits, popularized by controversial figures like Josiah Zayner (a former NASA researcher who famously injected himself with a CRISPR concoction on camera), are readily available for purchase online [cite: 42]. While these specific kits are generally designed for benign, educational purposes—such as modifying *E. coli* bacteria to grow on antibiotic plates or altering the color of brewing yeast—they represent a profound philosophical and practical shift in biological accessibility [cite: 40, 42]. The ability to manipulate the fundamental building blocks of life is no longer constrained by multimillion-dollar institutional budgets or strict university ethics boards.

### The Accelerating Biosecurity Threat

The 2026 landscape shows that safety norms weaken rapidly as the user base expands beyond formally trained scientists [cite: 39]. The DIY community has already normalized the self-administration of unregulated, unapproved biological compounds. A growing subculture focused on personal health optimization frequently self-injects experimental peptides sourced from overseas manufacturers and dosed based on advice from anonymous Reddit forums and Discord groups [cite: 39, 43]. This behavior prompted the FDA to issue over 50 warning letters to peptide vendors and conduct federal raids on major domestic resellers in 2025 [cite: 39].

When the accessibility of CRISPR is combined with the rapid advancement of artificial intelligence, the biosecurity risks amplify exponentially. Open-source AI protein design software can now generate tens of thousands of variants of novel, potentially hazardous proteins in a matter of hours [cite: 39]. A recent study by Wittmann et al. demonstrated that using open-source AI, researchers could generate over 75,000 variants of hazardous proteins, and alarmingly, found that existing commercial bioscreening tools could not reliably detect them [cite: 39]. Even after the screening tools were patched, subsequent tests showed that AI-assisted sequence design could still evade detection protocols [cite: 39].

If a rogue actor or even a careless amateur biohacker were to unintentionally engineer a pathogen with enhanced transmissibility or novel antibiotic resistance, the consequences would be severe. Because biological agents are inherently self-replicating, a localized laboratory accident can quickly escalate into a global public health crisis [cite: 39, 41]. 

While the DIY biology community has attempted to establish informal self-regulatory norms—even exploring the use of Decentralized Autonomous Organizations (DAOs) to review the ethics and safety of amateur projects—these informal structures entirely lack legal enforcement mechanisms [cite: 41]. Over the next 15 years, as noted by the World Health Organization's 2022 Global Guidance Framework, governments will be forced to implement stringent, unified digital and physical screening protocols at DNA synthesis companies to prevent the printing and shipping of dangerous, AI-generated genetic sequences [cite: 39].

## Scenario 4: A Patchwork of Global Gene Editing Regulations

CRISPR's rapid technological advance has fundamentally outpaced the speed of international law and diplomacy. As of 2026, there is no single, unified global regulatory framework governing the use of human gene editing; instead, a highly fragmented, "polycentric" ecosystem of national laws, advisory guidelines, and professional norms exists [cite: 44, 45]. How a gene therapy is researched, priced, and eventually deployed depends entirely on the geopolitical borders in which a biotechnology company operates [cite: 44, 46].

To navigate this landscape, it is critical to understand the regulatory distinction between **somatic** editing and **germline** editing:
*   **Somatic cell editing** modifies the genes in a patient's non-reproductive tissues (such as the liver, blood, lungs, or eyes). These genetic changes are strictly isolated to the treated individual and die with them [cite: 3, 23, 26, 47]. This approach is widely accepted, regulated under existing Advanced Therapy Medicinal Product (ATMP) and gene-therapy laws, and forms the basis for all currently approved therapies like Casgevy [cite: 26, 47, 48].
*   **Germline cell editing** modifies reproductive cells (sperm, eggs, or early embryos). Any genetic change made in the germline is heritable, meaning the edit will be passed down to the patient's children, grandchildren, and all future biological descendants [cite: 3, 23, 26, 49].

### Identifying the Regulatory Havens and Stringent Markets

While virtually all nations agree that clinical *somatic* editing is a positive medical advancement that should be pursued, global unity fractures immediately when dealing with human embryos, enhancement, and germline research [cite: 44, 45].

In Europe, the regulatory environment is highly restrictive regarding the germline. The Council of Europe's Oviedo Convention specifically prohibits heritable genome modification in ratifying states, and nations like Germany maintain stringent criminal codes that severely restrict any research on human embryos [cite: 44, 45, 47]. The United States also effectively bans clinical germline editing, but does so through funding restrictions rather than an outright criminal ban; federal law prohibits the FDA from using federal funds to even review applications involving intentionally modified human embryos [cite: 3, 45].

Conversely, other nations view advanced biotechnology not just as a medical frontier, but as a matter of national security, economic sovereignty, and geopolitical influence [cite: 50, 51].

*   **China:** Biotechnology is designated as a core strategic pillar of China's 15th Five-Year Plan (2026-2030) [cite: 50, 52, 53]. Beijing has poured immense state resources into establishing biomanufacturing as a dominant industry, aiming to become a global leader in the bioeconomy by 2035 with a sector already scaling past $152 billion [cite: 53, 54]. While China did impose strict criminal penalties on unauthorized germline editing following the 2018 CRISPR baby scandal, the state remains aggressively supportive of somatic clinical trials, heavily utilizing artificial intelligence integration to drastically accelerate drug development cycles [cite: 47, 51, 53].
*   **Russia:** The Russian government has officially extended its massive Federal Scientific and Technical Program for the Development of Genetic Technologies through 2030, heavily backed by state-owned oil giant Rosneft [cite: 55, 56]. In 2026, Russia's Ministry of Health introduced sweeping draft laws establishing special legal exemptions that allow clinics to bypass standard state registration for "individual gene therapy products" manufactured for specific patients [cite: 57]. This law, set to take effect in 2028, signals a highly aggressive push toward rapid, localized personalized medicine [cite: 57].
*   **Brazil:** Rapidly emerging as the primary biotechnology hub in Latin America, Brazil unveiled its National Bioeconomy Plan (PNDBio) in 2026, aimed at boosting GDP through sustainable technology and genetic resources [cite: 58, 59]. With the world's largest government-run public healthcare system (SUS), Brazil offers a massive, centralized market for clinical applications, and its patent office is currently seeing surging biotech filings, with 86% originating from foreign applicants [cite: 58, 60].

### Overview of Global Regulatory Postures

| Region | Primary Regulatory Approach | Notable 2026-2030 Policy Initiatives |
| :--- | :--- | :--- |
| **United States** | Strict oversight; somatic trials encouraged. | Ban on federal funding for clinical germline editing remains [cite: 3]. Expanding CMS payment models for gene therapies [cite: 15]. |
| **European Union** | Highly restrictive; Oviedo Convention signatory. | Harmonized somatic ATMP approvals via CTIS [cite: 47]. Embryo research tightly restricted or criminalized in several member states [cite: 47]. |
| **China** | Aggressive state-sponsored commercialization. | 15th Five-Year Plan prioritizes biomanufacturing, AI integration, and technological self-reliance [cite: 51, 53]. |
| **Russia** | Push for technological sovereignty. | 2030 State Genetic Program [cite: 56]. New 2028 laws will exempt personalized gene therapies from standard state drug registration [cite: 57]. |
| **Brazil** | Innovation-friendly; integration with public health. | National Bioeconomy Plan (PNDBio) [cite: 58]. Leveraging the massive SUS healthcare system to deploy new biological therapies [cite: 58, 60]. |

If Western regulatory systems prove too slow, overly bureaucratic, or prohibitively expensive for novel treatments, there is a significant risk of rising "medical tourism" over the next 15 years, where patients travel to jurisdictions with more permissive laws or faster approval pathways to access experimental CRISPR therapies [cite: 45, 61].

## Scenario 5: The "Designer Baby" Reality Check

The most persistent, heavily sensationalized myth surrounding CRISPR is the imminent arrival of genetically engineered "superhumans" or "designer babies." Popular media frequently suggests that wealthy parents will soon be able to walk into a clinic and edit their embryos to ensure their children are highly intelligent, exceptionally tall, or athletically gifted [cite: 62, 63]. 

Over the next 15 years, this scenario will remain firmly in the realm of science fiction. The scientific limitations preventing this are twofold: immense biological complexity and severe, unresolved safety risks.

### The Polygenic Problem and Lack of Control

Traits like human intelligence, personality, and physical height are not controlled by a single, easily identifiable genetic "switch." They are highly polygenic—meaning they are influenced by the complex, microscopic interaction of hundreds, or even thousands, of different genes spread across the genome, all of which heavily interact with environmental factors [cite: 62, 64, 65]. Currently, scientists do not even know all the genes involved in human intelligence, let alone how they perfectly interact with one another [cite: 62, 63]. 

Attempting to edit hundreds of genes simultaneously in a human embryo to boost a complex trait is currently impossible. Even if it were possible, it would almost certainly result in catastrophic, unforeseen biological consequences [cite: 30, 64]. As CRISPR pioneer Jennifer Doudna has cautioned, genes are deeply interconnected; editing a gene to theoretically enhance muscle growth or intelligence could unintentionally disrupt vital immune functions or cardiovascular development elsewhere in the body [cite: 30]. 

### The Germline Moratorium and the Shift to PGT

The global scientific community is acutely aware of the ethical and technical dangers of Heritable Human Genome Editing (HHGE). In 2018, Chinese biophysicist He Jiankui shocked the world by announcing the birth of twin girls whose genomes he had edited using CRISPR in an attempt to make them resistant to HIV by altering the CCR5 gene [cite: 3, 47, 66, 67]. The experiment was widely condemned by the global scientific community as reckless and unethical; He was imprisoned by Chinese authorities, and the global response reasserted a near-universal legal line against clinical germline editing [cite: 47, 67, 68].

In 2025, major industry groups—including the International Society for Cell & Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), and the American Society of Gene & Cell Therapy (ASGCT)—released a joint statement calling for a formal 10-year international moratorium on HHGE, effectively pushing any potential clinical applications out to at least 2035 [cite: 49, 68]. 

The latest safety data robustly supports this ban. Recent high-resolution genomic testing on human embryos by Genomic Prediction revealed that attempting to edit even a single gene using CRISPR can inadvertently cause the elimination of whole chromosomes or large, unintended structural deletions [cite: 69, 70]. Furthermore, embryo mosaicism (a condition where only some cells in the dividing embryo successfully receive the edit, while others remain mutated) and off-target mutations remain major, unresolved technical barriers that preclude safe clinical translation [cite: 34, 67, 71]. 

Instead of risky CRISPR embryo editing, the immediate future of family planning for genetic diseases relies on the continued advancement of Preimplantation Genetic Testing (PGT) during standard In Vitro Fertilization (IVF). Rather than *editing* an embryo's DNA to fix a mutation, reproductive endocrinologists simply screen multiple embryos and select the one that naturally lacks the disease-causing gene for implantation [cite: 34, 69, 72]. While CRISPR is showing immense promise as a highly accurate, low-cost *diagnostic* tool to identify chromosomal abnormalities (like trisomy) during prenatal screening, using it to permanently alter the human germline remains technically infeasible, medically unnecessary in most cases, and ethically prohibited for the foreseeable future [cite: 73, 74].

## Bottom line

The next 15 years will cement CRISPR as a foundational pillar of modern medicine, primarily through the advancement of non-heritable, epigenetic, and *in vivo* treatments for severe genetic and cardiovascular diseases. However, the true measure of its societal success will depend heavily on whether governments and private insurers can successfully implement outcomes-based and annuity payment models to make these multi-million-dollar cures broadly accessible to all populations. While the fear of genetically enhanced "designer babies" remains scientifically unfounded due to the immense complexity of polygenic traits, the rapid democratization of DIY gene-editing and the highly fragmented nature of international regulations present urgent, real-world biosecurity challenges that the global community must address immediately.

**Sources:**
1. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYnHVQzdv5EFH8268i8AKQdUpy0fn-bg1ehxtbX1mSTBPu-BQUvHVUestLbcvhQOgJg30z0Itr7r4DWq0HUU9Ed4TnyaV4RtQC1wU1Ww8rw_4akJZwWKJH2-W5AIq25OGtLBfC-2Jt)
2. [tbsnews.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEVi4SVVregO5sW1zUhYFvkzYBb4_9zvIelUImfb9V78_HwnSjZi6oNQMOhphV8BCqONxQ2ksCd2P20HLFZJDxziKTIVr3otpcLsvYGrlAgER8KnZRARoDj0izmxRyhFrl-X__vEWd9yKJNow9SbdXaNrYqhFT-4xWNonRGvbW4os0N57QeR0IY)
3. [pentucketnews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFXU0k3paX9g0Ci4LtkCV0B9IXQY_nHGF4rkk8LyHZzfyxs8hc3ypcsKK55fe1V8NnZG8BOkywE5i1Wj5a8qssOhvyYNczE7R_D7lK8efK-BF6o0lqR9eCx7QuZbelG062UBdJ9b4457NTbHcP0vx61QJaW0y7SZWbJaTu3ABMWkcf6ErDJNlE=)
4. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEcqyVU2qvU031YxvflD_K9Vb-r3iKY37s1tv6uTR5A7CjjNzM6_bytW-qAnTATn_3QdzJAd9RTNwQN1s2I-DxT1s32dckxzioZ-sJXE1ko7Kzknum8Htmib8_5e82PTGrr)
5. [innovativegenomics.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEA6e9-FNSDna58FF9wyZcR7rOrWisRtkBUdAHDnL9FAiWA7VxcHCnDYlLghCwDrgmjZuk3LCCY9XGBL5NSh_gcuA0pJraTnyxX8W0y8rpnUS_AHPR0kFoTw7BsYi8KuPAZ0HLMh1Hft0vXHps47RnJ_IsVL1Mn)
6. [theplatinumcapital.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTmUyogha3JHkQoR8Tz-YnOzOiUjH0vxTNrplzdeOUlzoPplgZzMGT1CjyQCcpdI92L0apCn4bknHW4KiyoiG98wDWRWN0oEbH9sDSbcxbwMqfN3VKwX5yRdTfh4FwiRT8bmM-Y6adk3WfJLmb_wOln7owGKIjO4I-Fp5f9pD7Zq_kmITCTAhhUrAwPwRnY0gG9uT6sqM8p1vh0Qq33EEiWCd7LspjCDgMXzT7G7PD-7Kx)
7. [clinicaltrialsarena.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEePSvbYbxsKgl6HWknjTiSbhG7Pgf-ThM10hXPundh8FjK7QWI32ESu9trJ4mdxxeAYBP8wm77LCO6i7dGm9SPgIajhQehlvdUYDCA5o29dJNQFKxT_mTNv8o15kruGdKwjaE0ELAKnyErITVD9Qd5SMAIVMZw8d9BbiNF3z5EbYb-MLAEx92Lp-gNwhPrAkHSVtaaTZ-AT4SNDJQxOetEBWOrXL-6okOgUS-p)
8. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHQvlzuKFFUtBDkHvxQlTJfFpUvMlMnsFynWemNDGNO4jWIlCG9YwQEWpV0S4W6S0IlOetSAn5zP_OuEnHEfN5K4jHh3vd_OusUhdAG8f9soawh1fYcGx0o_RoLPDRowDTLdAa7MVr7m1owF2R1NivBq7Cy_ob0_OkAMpQXcPKN9Qm9khSBRIQAPLD6IHpYtCs41E3rD_lZYS2hAWTAL18WX9bAcrrqDFkqH04bnMBUstKayv9Nfq9GjH4QpY_cXWPU1D0XT_6a7rQXqUV_MbkZkf52CSEkH-7g-BzSlDyZhd2jAQ4f55lYJgD5pET7qA6LQWNpNvurOUjqck-MQjlyZkra5abasPwB4yKrZvORXJA0tti6zA==)
9. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0LI_o-Y9tZWn_SwQCdEP4mmnnTZFCi-qye2YS1SDAIZByOn4FxwVruqpuCVy-SRCVbrAVX0IUO0FM34RoE8a735YacMIM3s1XSFAdQRKBi5HhoNSkBxLA-VysqHa7ZXBFxsCx_qSaav_OlgoJoza0PAF74ACFhv_rtb9ESG8QTK4TUdO102VY4vBZI4uOZVv5EG6uXKH1NyRbak5esnbwAy1SGNfKsckopYytKoxm7Uw=)
10. [innovativegenomics.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDFfq1eYnoMrKfNhtNb9Qp3js5kSDfdMMBBqTcNaFVsyClQMDWVrVMd8KPlFkBZRjmqlaCp-akHKKs85Dl-DQtJjEZ2A0NGG7uV_39F9qJ_1O5py0BpXyacjayC51E4lTEZLeBqDSSIBpupHTocYaZ-bZrBA16)
11. [crispr-medicine.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFsXkw6yXEQV88EX0xaHe6wRnyYvqrLxm6RaXzs8n0eM7rJ-RKDFxGduap7L1Z2p6tRWFZqsTz-wURhHntT6W4CyYln0J4FuSrT6i9F6glcCgCq8lXMnSwRpGXUfYVpFIJ_Bb37TaC7sRxYiX4dMK9kgXRxLkaYS5olP-nJCmKvZKBnrJ6s)
12. [innovativegenomics.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFwNvGWDYQ9k0WftIATlGfyC9R-_oa-fQEMiKbLv22dpHH6dntXlwmWMXnVbZzxiGhCB3eHB866fHStW23fQ_7VQk-vNpbhJiuvjrmrbTL7eQkpPZwWc5_V3FsPLfya0jX8JOLt1Y7EPYcSEodBK4ZG34g=)
13. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG8U3T25y134Nqew_sBQWrsFNWUvz3DCYfzZ6WzXSiYMEhjkBoJS1eMRQBgJJVbjRYjhYBV4x4XJixlWZRCBUxILnE5NutNJ4t0qugSOoUQzHGp9IcTfFA43BWiOwWbJCXn8vBUEnB3qg==)
14. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjPfpCOAw-OMaZuJUO8Oh7S1hgdUiiz1_eK1Glg0wnPBUeIQLsIEgWcorJfP7CcVPSXSjKqAzgncJp8XYCY5ARNqRh_oBMrvYyr0sf9Dqwlnsjv_eXPQhUhP-FQQIxmuzn3dG4xK7fQA==)
15. [cgtlive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0Cr5kJorPF1HvwZEDmItzM77c7Bc4QE3SX_t0uADGxq1SyDNq3LveeoUCLcOQor9BgWbySfRDsGmVdrezgFeA3kh5NaGXkcN8VcAufjVrX8Z4mGBhUdoHUTGIsUnXF8UzYnHV-KOUB_crDcG8xtVo7PJkydLAJfoxeDpxSuQ9a-hXX3GX)
16. [brown.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiCFEQ7PYWN5GWXolV_VEp3cok5OzNg6GOu2mYn9cn6EUrWfRVCWXAv0XGVdHOJft4WyQUjQoAYir0VSZfHzMjukhTRMpAGOLITbF8V-AbtFU4yECfKu_vQszB32rQXIFhBmjHRog2Jk8NjIND4GAxziWZo_J7pj-Y-Kx2cMadU1jwZxXWPVeX99h0zV3zg4WnZU-rPxw8_I7Ge7HYuNnRx0K-3agxRFzQxHnvwQoGoqcU918=)
17. [theactuarymagazine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWciGv2iXz6zrcAnYr41Vid7iNDVnuO_X0ULz8eBRH00d-q-ibGsIQsBJT-UwSpZcBmlEYY5pHkHpxG2EbNGS-3fq8rJzUdm07_1IgpqP8Y-ujTz3FajVUKSmf6v07QaBKU0YxSIQ0-XXdHoF6Zso7Y7hjlhOz95I=)
18. [usc.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEM4chbgFjCHW0eMAt7NJBYbgIMb55iCyF1MyDlOc4SHGdGo9njYNDqaNWTaqLRS7XF5zCJyD1JDojo7USy62sxA2k-WpGytbcomDxgg3cMK34ydliDeivt89FoecnPEyN-ov9Wuax1RZqaxWkAOOE0dxbOVQ==)
19. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxKKd4kuePM43dzOrPq8ESMlCZgPrw3wwfqMh5V3uo8WTXROTv1vTO3pFIHGWxcfn-ZS4NE245iDgujtfN1X1iPR4zsawNOmIzyT3LGHQ4XSbKqg5wfxbogbsxeWewFR9rj2eDMbLDx78Y7Y9JOQ60rry_lX7shmhGSOxNmdcNXJVUOvpf4HibSMWqvhn6t0R0owcX2YBiLcT67Cto4xq1bRMGbMORKpYH3b2KGTssqOPNtcLOW6L7v2LiGhCYTJJ2T2YE77jcpo4CKO7fLH3tldUScgMWJq3kzeWLZ0Sr9P8KW8kgwnhLzVF_vJooOxYM6b2LxJikJHSLBbiteawSxQ==)
20. [intuitionlabs.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxjxhYeLuv8PQWIkAJePL4XNTiEP4u-hSC6DzbevGjZFoHxXWTQ-ORD5MBUdI-RCS4RVm4hKPE73THqXNOxxNSoqc7N-cWY-4PCyE9B_vi0EMz5ouJcRPVNLRgyuqvqdzIKO7UEZhd3_9gZB2Ktl5keJO9jzW_)
21. [remapconsulting.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHO6E3hL7Gb8uKWdk-7THHcL-2j3Gr6TP5Z0w-D-5CbcYk88fBAt9pcDG2NbRZKsOKnF61ljt797sl7P2_Boua1Q9jTqNni7fVvQVuBhGOaQQU88PiB7YY5pZd0cnrk23EISEPPQlMu1Kz0H3IuikVCmA-lWQRYWuGttUX55fI6Lfj-iQ4IJC0UwlYquZ25GXAXxS40V0nB8Y_wb4yKahJ_HxaCgZpoGn3w-hhcUoLDNKoAaw==)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8-9zRMSSnmFdWrKo28k0GEgRzT6gxqerCpuCeKbh_33AJGJjTST4PxzX0LOdq4w0uUs-EkxoCw7ntWOougw15hIva8fy9pAuX2XbJQXs42-W-xPB1cGIj6OhJVZcfpBke6DpQvnYT)
23. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPtyJcB125bfKo3ait1sAkd0vpbepH8uNtP6Y_mqSjRY4zPVee3ZLPsLxo97ovJ6K1LuaP1C0c5hlPM1E5t3nZLCLqgksZ7pMsUqUmYg5E7s-5i_2uHki1Vjztugy-kXjsqUY=)
24. [techhealthperspectives.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGoTBWPNTD_ttlseGEx0HDbJZXBjsBvLoPoqNHwmvEjq8kHoFbRjrvqofOCVLT9S-IwPCKuZrzCe56UWQc6oV2XKCSQMj3KsxT0E8BaAJv3jSPZhVLZsZsfR0Yt44bFHP4puPi6zrbZ586i6uKd2QanCRDG8E4_KVIFj0uZFzfRYED3K_U8qqrfdbrN-K3CuqnXfL0elRPnzw_Z_T-84RUKFzShvwTomD43QI0=)
25. [genome.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTFWzWKMi0JpT6Hhekc3Tfzwx-LbGrpx7UWlp5LF8ecbr-w5RmK_zQmo6PWuOa5aXXHPOSiMnQDiZkH4oF075cD2l6Jn9PqCneKwAPbtLgRUzs2t_340M8pEAI95d21BXJe09YWxeo0ZFE-w==)
26. [sammegct.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGQlR_FJhU5D1qcq-59xqBRgHmI8ihfGHb6mMZ5k8Rj6ZlzeB42k2Q8mCRGJPGqrFFziV-aKWazTYk_YZ8XCqzyncbOs_KzRYrYpEUNncnumfWrXXCtJThrMcJ7Rwbwmc-Cn_4c2sVWNeKKgTJAR3Hsx92akXw=)
27. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDogUEQ1LqdqvHjNdKcFU8z08JVozQV86BriGbAQPWQEktlqBkp5EWBiCD0GpUJkDTT-gFca0-w--lnV9_aBEySzVIyj7N0q-xgEedtmzCSe6R-7K0FbhF5Hvr68SPWNBKsUuEC33MpCajl3I5VXYOVQ5vv05RFKsuXfbRGC2PJ5JvP8VVsEhfdNojD03W5CjgQ9VAi1DNS-8YzJKAmek31sY=)
28. [eurekalert.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7pfTwnMTBbiB4guyMmv0e3BCmNH9E21U7yle1rSAWLHYyucetKQCP8zbjWru0qOTFDdF3ND276MLEgjYbGsjXxa_kCvOE8VGE9PkSjh5_cd5qPZmCF521FLUbbjFtbc_M0D7i46Q=)
29. [themedicinemaker.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3x8Rje5-rqGvNY3oKl_vJsI5lRK7cauQDoEB0k6uFWMkLDPyHBXaJjRIFhQ0MJ5uPF0Kfyk7VeKVpKEjQufwbjmx4y8vparsv9rIIZF_5x4ilMBTQfzGiTf4sWb4GqcLJF5zqERir8jqJKw-KFsUBx0CbIhUVrUJnFYhSv2mWrTJ_22YosuR_DWT0Rm9RfjRUcUvT_4oOqMtQYsCPrC8EBUc=)
30. [americancommunitymedia.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEaTgydwhJhQZ3lj_wQNZnbMk9Bl1ue-Pyxh4Cym2Xg-mYX0uayh7Z9Mex_yxvfYNsJFtyNWOxpgCbAi11mbhWpUN5fDua-3RN8duWIXnopDwJQ8O80EL-aKZ_pfUr8p3-ch6A76U6DIxRGjVSyMR1KxxRmo9lYpONUKQxBn1xZNsOPDWyT58Ta6TFI65yUVqxNvW3sZPwt_zdWYeM_aXdbMqbrg3YxBf169or3G_tRdx6azZlrZ-0F)
31. [nasdaq.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGyKRoouXJZadLHjl_p1XL7-3LXUtESMD7P6aq-BDP2byxcZh2RurSo7Q76KEL_IByixwhTpcRKAuCNVnLFtE5GxFkWUEHMn3eK_YIc0YGgAHOJ-gJ2HmjTvsGiZeEy7mIYYeV5QyjYC_Phi5Anyxm7eGOykZkisndMDtwLiO2D5jDWNLX0nL_elDh8vr9892AAzCOgFGhqw-WOju5Ne7cH7LbC_oASpRFSL8BITfE=)
32. [un.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa3EW0LCdItGxWLVpelY0MHzRfmup91pAUDyLmxHvrp7J1Uj9CdPw2bS17fzgToo-hyjhIlLCItlyvMzuwk5z-PUbrKV05LqTpJFncPQ14pLvz7aRbEgr0-dspMxg99lxqmEcqsKBH89Xax5NV8Anv7skdoaYfSZivgyYvGFkRRu3VttfIOMT-6116Tb0dNngkDM_7Qil_TZZAifof48-Ol7m9TFluF7majNhmkEFpKK1lMCQ0yGlhZlo1xTgx2Y69VzmJUTt4XKbtJVQ0WTIwuvIaNX4Bgdpa6OSqlNQ=)
33. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFroL7_Cbs0Ndl8_CNM5LSTsMWLZfAFZkUz5J51vJr17hU_72NUo6WI-xe-bHuYZjySC2KwI1L2d-wZWxxUZV7_M7PmXFBGV2ABdIBGfoSHCGAczFFfOXRS6QpXjLJkv67TAjGzcyWqaOZ0P_gFTg9SKw1ioQ==)
34. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzYcEjKl-JLCIkx1YlzBu6-nDML-ew-I6Met-FCs3kdqzCf8nkgfn_VEulG9EWgtMHyx9X_pyBxLiuwTnOVx7AkE1z3kXwDCwMkP65gDwi9ew0mmvwFsKY3PhpeAVAiA==)
35. [globaljusticeecology.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnhl2b46VypB7Cg6pL3iEy-lxkmdzUm1Iv4OGPL6aDviw9Q1x4XBa6nNTJ_BLnINc0JVAXSnSbCcgbogyLLdDFtyvIuLoPpzhKIeeuBUUCcrWQt_8fWf32BBb_4bIOkv99LvK0l7D7uTJEL3BD-XV-DFfFbuNQ7t_D8dbySM100klK)
36. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4nJYqR_lR7rzdOVhFwqOQgoEegc4PD5xilqudgzXWVt_fi0-6CH4eiHCPfhxbA8DfGOmbiEHibzLVro8bhzGpMJfvoO6c9VteoBJp0R-F7i34WKnrfXFjhhzO616ppp-LYN7GaU94)
37. [wjarr.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeOTB5D1QvfWGGrdBZrEzUSksrp4_094BGQCfpReKSrXosOfgcoqTg0DK_9b6Qq3QhLIrL2ciAquSLq84tnlyUKXEAgm4vEBIMvGSOwotCvMRGfjsyh1mwpjSEWm5HOJgssUNd5j9K03XW8GfynudUUYGb8vIBSVjC6qzp)
38. [cas.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFt6PaDbMDT2VH-4vK4KSAgTWVY3wTgpCaMETIkX759MXslKyhIULsVBXuNMxDb5zr_faG9W1Gd6l-rzW2ZsF-HC2UCqTEYXF30r6T3080pEgpDBOfCTbfav9TL2aNMl7zB2QHSuH6sw2HaO3b85HYCdGohZvtjlqwIvEwULDK8OiC8)
39. [effectivealtruism.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHgNXW0IGqh_rOvZnRpMuUPsiCh13u9Kw7oIzaKiFbh8zKxS3-7lmOSjlJmgwIYRBDYn3nC5r65J41lOHQ_TeeCQL-lVWWyPxlcCPMQFZQu5yWJlmLG9S0kzanX1FxZ6yJtBmNJEAjHePAInRPeh0I4GMin7ufGwwEdHNcoUlCDxIXXGwM-jNOrYyB9B9WRSIpJJQ==)
40. [ipscell.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEU11nDiWaE9a4QLjzgIfgbApwC9kCProHcU0YhgSNgIlypinUYmvETBDFhydmrl9ujj5oaR4Uj3CBs20qR6QbSEkvKDYyjjORqboYaXBycAPsessYu5d9wsH2BQJmlySGgd37jeidkWnzvnYsgFZ-uyomMgPj92QEJXw1E)
41. [lidsen.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNXU9a73M1S_tJ6NHD93SiqvUTaYW3YioJyVpfk3et6mavYRQuWc-0qOhA-72E3XDDmH_vi7aoFdi4Okfvak75USpTbmAMM92JblXr6zpeq4f5b_64MNLNNLXIxe-BUHqNQdp5MQI1eULsuyUDT7Wv2Q==)
42. [frontlinegenomics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTujxteMK2v3vBPym7En2HGspnM-Uy1Sm2awpANIDxrRnVKl0Fvb30M1_Fr_SVzodOZW3ZhxABJjMF5ZACOQoXlo5WjE92AmfKReVHPztthl4Y7AG78xlOAtDGc4RlN5BHKL-dd5g9D92Cambl3uMtFl0mL8ZaNG2SXAuSWsZLuxhkjczw)
43. [medicaldaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDbBOCOa-W-DUHrqTeTdgUvcNDpGuAcswCl_8LtH02YKGjorbSGvUye64LRgT53wNkb_GFXZszZElAOy9EvoOUeweVg-7LobVJSni_-brrXyppd8k5OCQ8XMEPOcqja7-9FXMIiW3LKY2hWvC_Dfc3fT76dIrNTmTQCd7hKCFmE_FjqT_bZ9n0jh8Xnyx93ODBVObDZwC6gLo8UbNvnNXDeKwaPuk=)
44. [consensus.app](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHbUJBoqXYDma-N7dz6hUs3nZpLLUKWaK00SLo_WL4ca-8DtNBh6iAL7Ug88IExShJUdS-2Zl-3v8Xw25fg0XIDwQC2qLh7cQ6O6P8gvXbs8xTnqbQLA9HsiNPHVwPpB3yTMKzA4apb3oyM-b80QuyjGoGrQtVzF_OB49Luq8gDMzJQAc-7OUrLMUmCGwZlUig5aYYMzFSSjDL8khXU)
45. [issues.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENoWA67AJ86EARJGwC9MOCmHGVfNVYhgWksWXMvjaFkSUey1drLrSUsfc8KTSJ1opbwY2PK0Hp8wAgOFe6dVlOnR3BeXJcYNGZ6bSnt9jQsJupMiF_u1eJvEQopO0U4I6oBfqUynARnygaydHP9hyNZypOEmwiQ3fwbQ==)
46. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFLa2JIbju7C_Pcb58sxSWao6__9E6t822VwxSgI7a0Rv0pgf_FrSMqzrP_v6zMwahEc8t-XnXORHC2vl4E-oEPqywQT4TBhEXqH6H53h0ZcPlylH7i46uNj9AR5_zYiR_1d3Y=)
47. [pharma-journal.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjUirrv0qMLqorL29ufW1tP6c_-rsfeszWoaRpq7HzfIElTnpI3ZcUpFuQ-bsZOZaipvUkJbi7SuR4mk6kncaPSQeHOLJT23JkR5IQrbbD9r0S4Pz4xZ54tr95sTQzaut9f7ue4tbHnHHBHqm1Yfd1Ne_AWZyY96Og-X8=)
48. [phgfoundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHnAOCHQEHd3RTW7-BKYQebtHatRTYy-nstqk0lMilsDMQb_PFOWKzdjuJKM2ZmCqPNGI7rE5tAaYrznNKPST5WKGu92NT9Paitiqp0kK3XML5rxpkGAHsS6fR45BXSRUE-MLgjAVeEADFrl6gd0FnibqKQ4dTH46Ghi6QAROnF71toHTfjHZS09H7FgoaN95hB5fvLnA==)
49. [fiercebiotech.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0XTE0AulbkAiwGji8Qe2x0qiMNMCai4mfl5kWd7rMHXFagjsES7dHCpK0FqQTt2BJqb9X6punjGVamH6VtH9yOfdUbgPDNXWHdBmSM7SWBQiQrbIpBLQDFGpxcFkfOU3WYPsOe0DpDe7UcdCeDtxhCnNUoY5eQMNfkNFMIoYp4EPYgjzQDZQAGdYIX9-_CZtbAQt1Uh81vPmQiQ1B1LuGnj7q9Mckbs4=)
50. [greenqueen.com.hk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGkFzYe5HerWhp2eHwbwckeEeFQ1RW3zHDL0ijvBTh5i-UkFFDViOAXc8FuUVbqe4waz60Z8GwcoKTmtdB4aoVxQqrsNoa0gpRx3WdLJu48VPTwZ1dW-c1if8-VVZWZv_9XyQDc5r9EZ4bPUaom9LZvB6dhMYvzgu5zKO0_u_LrnCefpQ4g_eC3ew_tBY9juUU=)
51. [meetingsinternational.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRKEhZAByE6zDE4Nk4_pcvlHKHVf_SYK6CEfjhUJwI19VDxDcgj6Sd9tymJrNEp12K0Jgia1PJT5y73nyDxpLrG7nNKoWO1btd7zvavzJ_vhSzLs8bXYEWQWP_Y0cIfyA4I_zrBqWuv7Vh4oKZ_1trX-OUgJQpNsyDGA-J4-dyZaaPZZR75Ir-LPWazmPsTPy-l94IF8IBBAuw-ezrZ2Lsr6uUMWe6dOipRYw=)
52. [winssolutions.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEK5bThBTmI4uQ4GN4fYj31EAo68AcxZletFmBlzqitxQJhsAJhFAWK9BDSjQWaTLcmPoroZMZ8sV9KQJ7aEmtGW6qK_5RTSa58l6W8N57Hr3WuzeSdOMtOfS_ukfaJc3YmZHn3DfCOuRdzBylzeXkwrw==)
53. [chinadaily.com.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9figAeBVXIKtlFMXPQGvaWl0TgfVpwwj1ZZs9ECYJXBpO4dPTk6RefW21agjhMKrFz6oPmg5EmgR8NOwLO9jSXPJpAZSv_uzg_FnUFwCuksdrDBZdLTk15xaAqeOV3_c8Btdr2qOUIjfI-8K9dy-p4m-n_5m5VEVITcmNRnRX)
54. [scio.gov.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHSN2ni-z40jxknTuMpE6m_jKLGhQ22-gggL0_qVczvw475_KsTVMMTwWgbJwIgLnRUjc3IP69k99x9sLhzlNGy_X9yc3rUhHI0UV2RA1IZFhCbS7hMKUT_esluGvxEyL79o_Dz0Os_Wl347Xm5797PGG9_DkAZZqqRa3Ptk_WmkQ==)
55. [usda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1PWpafOjVAlFVtmvgzpVtl6rIPCkHOVYwkDHy4ohvhOkIf5eFc8Uf4sKC-d6UMG1_c9c8ziJ-a8i2X-bRJk943pNy6OZp_3HVgtMzYK8pj-9m9WoU1pmH6eaPDSGDT0SCKMrn7EQ0bw0rVoIpMdWgmb0PhMBi7H2HY0u9IFlvp-V8X69nlqXRDJY6d_1EMWAbFPEXLZpsOokQNRG_1SzjRTht6KWirxh8Xio8m_5oftH-PdZWJbl--31Qyq5gOLlky-uy3BfhncEVrlIfmtRPok84XIYbLYuz3tkwL1QBxQ==)
56. [akm.ru](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGodb09qik74G_vbaxZb72r5yS-ls_eN4vRxxYVCRWP66elYY5zoBoTi_z__i_AaYujfI6bPSzGK2DG2rlZglqwnFW8RsHCPn7rGUWyw1daJqn5PvvrSXV2DpTCD503jeIW8meLkEqficP504l8SfKEd6REXlrYOrvIIH4wgppp6ZVXYBPjsk4DDn9VTeJAzmLFSaNeSLJrADZw6SMValwelO9gutfQzK1_IIEOwjwnjxLM4takZAT5zQ==)
57. [pharmprom.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGX44ZZaDERPungEgeOPxwSHq7yRwVkQQ23LjTqzYPJA-2XhC7a5fXWDdYhfF65Bh6XpSkKPn1cyMbTCPLIXcLrOsKb1UakM42R4kv1g2_nmhB_DcvzoUUndElUJ3GUZapqFGdMLuY_o_VsRkjtZuvhvb9cJG-FRGozOwZBcQB1pSCRkvKo4Sic2iVLjdCC7T3it1Tpq1KUeA==)
58. [ebc.com.br](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGp98hOYvI9DDYx8Tv5ZyPmJ81C8kz-p5whVUf4vNKlwRCvuQCYe68P1TO14DBA4eWMSAT2xjTQvcizBTWhsOp4Icj9buOW2W3LDVkKOC7kM50I3ayx2KlHAnRDNw9DoksMUsYTD2XHiKcx7rJFytOqUncsWfSmeHSqUsvQyfUZE_VcAvbDL5U9djZCM0Su18vJ20K5TTMubk3dUoNoSY=)
59. [globaltimes.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgBP9Ufl9AjAH_pPbQXKpmBNAn8Qio2o7AU9zkPtGlW2Nk2SC6qJ3XXbYHY8qNRPwSVHRwa88Q3RybT-Ot6dOeP-vB-xpXbYid71VuTcCWvoA57nby9zI-pVoL2O3Kp1vh16eKrKYAio7z)
60. [daniel.com.br](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJPwPLWCrrrOmmfCk3tL96eMrFDu7CA_48Cc0Oh2FG6qgbjDMIKVLv7jzw7cPeEtR3ztskWOfXL4Wwemzh82s7XxsvwXIGgMzk97ZFrGyn_y2cGwq5xs8p2LPTN3oQ91aeyoy1w6XNbb0OlInT3hoTX6WWgngPImAs-Vc0V2y6HwiRHNpdPguJCJg4ATCSHypYTnuOd3jjohWQpHzB-8c=)
61. [dental-tribune.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE7EO03voccZUVbHRULz-jI74oMTB9IDJprZsp0_DbYi7JqT9hHVhIL4NWgHGHziiszV_oIh5OGmQfqKj0Ku-zMm51GWt8WcMisxLmq8xryghd4OYsVP8OfMtfC9sZ-L91lla0rO8gsY0ybGSHWHoCbchcyhRP030YRTZ5lwdaQ0IG43Hrv5jqe3WGSt4njiBn5KbRX)
62. [idtdna.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXDS6w6u3xeFVZBddNBPC6iFfJHtOF-OPZvMBZgzKQaQ5maU3LTAFgSMnUKke7A4XFt0Lkk0-WnQsez8KRTRjhkVN3ezivgiYtuhd3LyPnHvLvuOlWOGk-6Ejtvqq70WGQBvGuRtgUSPjuAqyE6ct3Ge6SnCkYDhitVTrFJGNb_4lNZRTZoD4EIyZDNho7leYYtrJA-pJjn4aY48BsKsmwVclOGpQ=)
63. [biophysics.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHrzUjIwzWKRkpHANka66PmC6NKUFGxzzcZa7ERDzUOIWjT7OiAhKXsDvfus3Hl9fLxJ6P8faTaf69mrpPgLZmnJs0hN7L__KVWZAfVN78zjnivZlyvtE5n_nQH7Uyo2P2HWpDiAyOEnKIp-ROrTa7vNSKHfR3CDB2wYVShTv3CdfcCzguS)
64. [reddit.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGaDgDi94Z7Nt6e1rMWYMkWubOalUB77lb1MAJ9jLx1b0VzccOctTU7IU1UvKQU58aDOvTDv4TlJV4bGx6dFB-D1oCeg5K8ysPpd4r-5PIPTGjNRjT33ecuSBOb9dsWe2ynNx7q5iZF03e4Mszg3HcpYeieFxJcaQlFD0IkhVhanWafLhydT4lBjvyGUVS-N5mGKVcHVORXha5j)
65. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFdkOKm_NCNeKYiYulJn6RNpVoX8MD91d0pfTvpck2bY8IBrqR833brREk-M2X-jzNKXAb5N6hgmYKaXNXpZpRJ2HICxuyG5iL9yANfP90GUQ2HLNL2F462Ik6g0s0TirXt95h-gDKgVQ==)
66. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUNSVYaUu8zkwC0CiO4KdQSbWDN8w3ItJY1vgmQEs35cCObLkvjL31kiPC_MU6hYwmYUK-jwGMRpfU6j8ukWn_s2YZkT6PbI3wxgjY-CgXVLUXbAaJrAb-l4-E2LPFlQ==)
67. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKHCaMQI53RGjkZKQUjH6Y3-_WdPvR35oScqAAj0Qu_Kg2u_lOTmH45TNhWwoO2-thDKs8zEMcCI83-qz_sWezYkLaXvGQJIrO_huHnnppB6PeY4bl0efKkxoU6vIXF2fJrlp70hNiKg==)
68. [cellgenetherapyreview.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeFAFxmo7bQpnxRlrp0HHEIfSJEF_NDPq7ObkTlNxZnZwbM9G7AmEV3jlZuDWab1nBjTj4FG5XO8spf_Q7IohpRksqCZiFi35jsunSr9exruEsjb1CB3JMdAPBcsyKfEP76qZI9z-JybIHUJlz5u6N2EqMpsV65t1Kv5kP7sEwByT7UBWbLvxMEcUa6YB2aIGeW0THd15pucRkek5fPUS-fh4mRKbsxI0B8OpuvrueHaiefRrK)
69. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDaYontk5B-_QU7WmM6MF_3b-xLHTlOfIsMKFGqdunv3WB7UwsYPWjOL7DHigHorjEc8IN11IXUHdS2V5gUcBRrhyGc13C3p7NUwfLRa9B0-HzqFj1-qzIfztDHqcJNN0MGwNHoRbqw5qbqij56Isr3ZvctrkdJVkMdjAJeYeDNw5TCbi9vkhgn_S6HlxTPpsG7305U7wHkSDkeB7-1WVmaA==)
70. [prnewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHN1-98Vkg7-hiyGh7Ekyr02EawjRn78uvsKo7qU17TyxHYkHOlgxtTs4QEPoLMhj9rEOrPiZTSFoE_z_JTxjqYSywsoHBUf5CG2qbBk3lZPCoiwnanfbD7Pjv4mF8U3isigBafw8_z4zKrWmA6CyVjVrOiBRD7wAsXzB9uX98rQWV77ee-6Hhm96QA7TjvKLBTAQEgyJU2hV2ElUl6Mv89UWxuWJTyDzvRPoxcrr4ODHSVPIaz-xgNtnOV2UjoG951)
71. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGd0Dxj4P4dQV0EP1mHG7VxfudMtphpPki1FtVb5dGKAzMBX8rkOSJoKd7LTHTgxLIwB35e2HJZ6_JrAr07-fr30TPgd29ibXE7o1eGryI2KK8oAjURHIs2tRq_nNYhAZx3sK24DBA_mYfmigSUGNVEgUAaPmGyn1h7bkAJwgaMNreP4S49CPQXsXPOfwXxZH6Io2rF27Fv2ADhax6NuXljrBdJWAAlMwMPhx3q27fyrAQa1iXRATvG5XZADe637NgbOQiApijOaqlx6DqaJyvpdSLHyJVboA==)
72. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG74IaS2OT4_YlcDyrpfZ5utehfaw6zEdfoZYcuBeAr4_JQqQ4iLS8vYKSlgNYghyQvT3wDumGCZxCGd4928nPdyWsyIWzUBC6ePhzihg6BfUXlgYELR8q0MYp074zDE0-659m-fAnnd5EnM_VtNwWdTy24TFqgDnSj34xa9lRJ2Ya5QrAZYJSnp3c3lb4rWA==)
73. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3nfPRc7Nahy0zZP_FWA4Akpkn2RA3j0T4rJMC2RJPJJ6l1fSWYT9S-ml7WVyVVUVLj0QUjHKPlaTs4396lrXNH4bYSwWrs6w_kg-UL1-kYxN9Ad8nMDQfNxwE_1Y=)
74. [mayoclinic.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHS4MVMeDo_KrK4TlPkpYEufqARv08iTydtA0Nk-bLWX7Vwf-HUOdHlhaw77H_ep7bAmuG6Q44LMyuMbDHayxhO9YJ53WcbfDVBEj9N-hQpQ0NVlLNvmKYwBcg5G4sAoh5AUUMLZiNoZAl86Q9VJNI4kEZ7C7jVkEts_YEtR68i0OgZx6KRn0lkLF7Cup333qzWoA==)